濟民醫療(603222.SH)與日本小田醫院共同簽署戰略合作協議
格隆匯10月15日丨濟民醫療(603222.SH)公佈,公司與日本醫療法人社團醫進會小田醫院(以下簡稱“日本小田醫院”或“乙方”)共同簽署《戰略合作協議》,雙方擬在深化公司控股子公司博鰲國際醫院有限公司(以下簡稱“博鰲國際醫院”)與日本小田醫院的合作關係、啟動細胞治療技術領域研究及臨牀應用的合作、合作開展細胞培養基國產化項目展開合作。
日本小田醫院系一家依照日本國法律設立的醫療機構,擁有獨到的細胞培養技術和細胞治療技術,在細胞治療領域擁有豐富的臨牀經驗,是博鰲國際醫院細胞業務核心技術來源。
細胞業務是公司重點關注和佈局的業務板塊之一,本協議的簽訂一方面為博鰲國際醫院未來的業務的穩定發展提供技術支撐,另一方面通過研發合作、產業合作,有利於公司拓展細胞業務產業鏈,對公司的未來發展具有重要意義。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.